# High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

> **NCT00131027** · PHASE3 · UNKNOWN · sponsor: **Japan Adult Leukemia Study Group** · enrollment: 240 (estimated)

## Conditions studied

- Lymphoblastic Leukemia, Acute

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Daunorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisolone
- **DRUG:** L-asparaginase
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **DRUG:** Dexamethasone
- **DRUG:** Methotrexate
- **DRUG:** Mercaptopurine
- **DRUG:** Doxorubicin
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00131027
- **Lead sponsor:** Japan Adult Leukemia Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-09
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2008-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131027, "High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00131027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*